Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

Psychopharmacology

Volumn 179, Issue 1, 2005, Pages 303-309

  Krystal, John H ^a,b   Abi Saab, Walid ^a,b,c   Perry, Edward ^a,b   D'Souza, D Cyril ^a,b   Liu, Nianjin ^b,d   Gueorguieva, Ralitza ^b,d   McDougall, Lisa ^a,b   Hunsberger, Tracy ^a,b   Belger, Aysenil ^a,e   Levine, Louise ^f   Breier, Alan ^f  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Anxiety; Attention; Euphoria; Glutamate; N Methyl D aspartate receptor; Prefrontal cortex; Psychosis; Schizophrenia; Working memory

Indexed keywords

EGLUMETAD; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PLACEBO; SODIUM CHLORIDE;

ADULT; ARTICLE; ATTENUATION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MEMORY DISORDER; MOOD; NORMAL HUMAN; PERCEPTION; PREMEDICATION; PRIORITY JOURNAL; RECALL; SIDE EFFECT; WORKING MEMORY;

EID: 20944439080     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1982-8     Document Type: Article

References (45)

1. Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH (2000) Lamotrigine attenuates ketamine effects in humans: support for hyperglutamatergic effects of NMDA antagonists. Arch Gen Psychiatry 57:270-276
2. Belger A, Puce A, Krystal J, Gore J, Goldman-Rakic P, McCarthy G (1998) Dissociation of mnemonic and perceptual processes during spatial and non-spatial working memory using fMRI. Hum Brain Mapp 6:14-32
3. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP (1994) Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res 52:295-303
4. Brandt J (1991) The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 5:125-142
5. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154:805-811
6. Brody SA, Geyer MA, Large CH (2003) Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology 169:240-246
7. Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170
8. Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237
9. Di Lazzaro V, Oliviero A, Profice P, Pennisi MA, Pilato F, Zito G, Dileone M, Nicoletti R, Pasqualetti P, Tonali PA (2003) Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. J Physiol 547:485-496
10. Domino EF, Chodoff P, Corssen G (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 6:279-291
11. Farber NB, Newcomer JW, Olney JW (1999) Lamotrigine prevents NMDA antagonist neurotoxicity. Schizophr Res 36:308
12. Gordon M (1983) Gordon diagnostic systems. Gordon Systems, DeWitt
13. Grunze HC, Rainnie DG, Hasselmo ME et al. (1996) NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16:2034-2043
14. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660
15. Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 155:59-67
16. Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH (2001) Attenuation of ketamine effects by nimodipine in recently detoxified ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 25:936-947
17. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
18. Krystal JH, Belger A, Kirino E, Gore J, McCarthy G (1998a) Ketamine effects on the cortical processing of novelty in humans assessed with fMRI. Soc Neurosci Abstr 24:#104.7
19. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS (1998b) Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 135:213-229
20. Krystal JH, Belger A, D'Souza DC, Anand A, Charney DS, Aghajanian GK, Moghaddam B (1999a) Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 22:S143-S157
21. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman R, Charney DS, Abi-Saab W, Madonick S (1999b) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies for neuropsychiatric disorders. Harv Rev Psychiatry 7:125-133
22. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman RE (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169:215-233
23. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869-872
24. Lisman JE, Fellous J-M, Wang X-J (1998) A role for NMDA-receptor channels in working memory. Nat Neurosci 1:273-276
25. Maccaferri G, Dingledine R (2002) Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci 22:5462-5472
26. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
27. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
28. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927
29. Nestor PG, Faux SF, McCarley RW, Shenton ME, Sands SF (1990) Measurement of visual sustained attention in schizophrenia using signal detection analysis and a newly developed computerized CPT task. Schizophr Res 3:329-332
30. Nestor PG, Faux SF, McCarley RW, Sands SF, Horvath TB, Peterson A (1991) Neuroleptics improve sustained attention in schizophrenia. A study using signal detection theory. Neuropsychopharmacology 4:145-149
31. Newcomer JW, Krystal JH (2001) NMDA regulation of memory function and behavior in humans. Hippocampus 11:529-542
32. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Kelly Melson A, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis. Neuropsychopharmacology 20:106-118
33. Nusser Z, Mulvihill E, Streit P, Somogyi P (1994) Subsynaptic segregation of metabotropic and ionotropic glutamate receptors as revealed by immunogold localization. Neuroscience 61:421-427
34. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533
35. Oye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209-1213
36. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12-20
37. Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476
38. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ (2003) LY354740, an mGlu2,3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6:189-197
39. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001) Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24:330-334
40. Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured clinical interview for DSM-III-R-non-patient edition (SCID-NP, version 1.0 with supplement for DSM-FV). American Psychiatric Press, Washington D.C.
41. Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R (2000) Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 397:R1-R2
42. Takumi Y, Matsubara A, Rinvik E, Ottersen OP (1999) The arrangement of glutamate receptors in excitatory synapses. Ann N Y Acad Sci 868:474-482
43. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25-38
44. Wang XJ (1999) Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory. J Neurosci 19:9587-9603
45. Yonezawa Y, Kuroki T, Kawahara T, Tashiro N, Uchimura H (1998) Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine- induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 341:45-56